

25
aaps

DEVELOPING SCIENCE.
IMPACTING HEALTH.







Preliminary Program

2011 AAPS Annual Meeting and Exposition

October 23–27, 2011

Walter E. Washington Convention Center, Washington, DC, USA

FOR UP-TO-DATE INFORMATION, LOG ON TO: www.aapspharmaceutica.com/annualmeeting



WASHINGTON D.C.

**REGISTER
AS A GROUP
AND SAVE
HUNDREDS**

**These Company Employees Receive
\$125 Discount on Full Registration:**

- AMGEN
- ASTRAZENECA
- CATALENT PHARMA
- DPT
- ELI LILLY & CO.
- PFIZER

**CLICK HERE
TO REGISTER**

**DOCKET
ALARM**

Find authenticated court documents without watermarks at docketalarm.com.

From the President

EXECUTIVE COUNCIL

Officers

Philip R. Mayer, Ph.D.
President

David Y. Mitchell, Ph.D.
President-Elect

Danny D. Shen, Ph.D.
Immediate Past President

WAYNE GOMBOTZ, Ph.D.
Treasurer

Members-At-Large

Jeffrey S. Barrett, Ph.D. (2011)
Gary A. Thompson, Ph.D. (2011)
Marilyn E. Morris, Ph.D. (2012)
James E. Polli, Ph.D. (2013)
Raman Venkataramanan, Ph.D. (2013)

2011 Section Chairs

H. Thomas Karnes, Ph.D.
Analysis & Pharmaceutical Quality

Mary Cromwell, Ph.D.
Biotechnology

Dale Yu, Ph.D.
*Clinical Pharmacology & Translational
Research*

Thomas Prisinzano, Ph.D.
Drug Design & Discovery

Dave Wallick, Ph.D.
Formulation Design & Development

Mike Yelvig, Ph.D.
Manufacturing Science & Engineering

Duxin Sun, Ph.D.
Physical Pharmacy & Biopharmaceutics

Lane Brunner, Ph.D.
*Pharmacokinetics, Pharmacodynamics &
Drug Metabolism*

Abbie Gentry, Ph.D.
Regulatory Sciences

Executive Director
John Lisack, Jr., CAE

Dear Colleagues and Friends:

I would like you to join the world's largest gathering of pharmaceutical scientists at the 2011 AAPS Annual Meeting & Exposition in Washington, DC; the city where AAPS conducted its first Annual Meeting!

Scientists from all over the globe will be gathering at this foremost event of the year. This can be your premier opportunity to meet colleagues, learn about and promote breakthrough research and technologies, and improve your professional edge.

I'm also excited to present a completely electronic and searchable Preliminary Program. This online tool will help you navigate through the more than 90 programming sessions, consisting of:

- 6 Short Courses
- 35 Roundtables
- 4 Hot Topics
- 31 Symposia
- 15 Sunrise Sessions
- 10 Open Forums

Additionally, the American Association of Pharmaceutical Scientists is celebrating its 25th anniversary in 2011! AAPS has spent the past 25 years offering timely educational programming and professional development opportunities to pharmaceutical scientists. During this anniversary year, AAPS has been recognizing how we have developed science and impacted health. This full year of activities will be culminating at the AAPS 25th anniversary celebration at the 2011 AAPS Annual Meeting and Exposition in Washington, DC. This is one more reason to register early!

Start exploring this online Preliminary Program now for current program and schedule information. And, the all-important housing information is also available, so be sure to book your hotel reservations soon.

October 23–27, 2011 are dates to block out now so you don't miss a single day of the 2011 AAPS Annual Meeting & Exposition, the biggest pharmaceutical sciences event of the year and it will be AAPS' biggest celebration ever!

See you in Washington, DC and Happy Anniversary!

Sincerely,



Philip R. Mayer, Ph.D.
AAPS PRESIDENT

Opening Session & Plenary Speakers

AAPS is celebrating its 25th Anniversary and has themed the Keynote and Plenary Sessions for the 2011 AAPS Annual Meeting and Exposition: **The Next 25 Years**. A panel of visionary opinion leaders will provide their insights into the shape of today's pharmaceutical sciences; the state of the industry; the regulatory climate and societal pressures on the cost-benefit of therapies; and, what will happen in our industry in the next 25 years?

Opening Session — Sunday, October 23

Keynote Speaker: Janet Woodcock, M.D.



As the Keynote Speaker on Sunday October 23, **Janet Woodcock, M.D.**, will provide her views on regulation into the future.

Janet Woodcock is the Director of the Center for Drug Evaluation and Research at the U.S. Food and Drug Administration. She previously served as FDA Deputy Commissioner and Chief Medical Officer.

Dr. Woodcock has close interactions with diverse constituencies, including the clinical and scientific communities, members of Congress and the

Administration, national media, patient and consumer advocacy groups, the international drug regulatory community, the regulated industry, and representatives of the Federal and State agencies. She frequently appears in or is quoted by the national media and has testified repeatedly before Congress.

Dr. Woodcock has led many cross-agency initiatives while at FDA. She introduced the concept of pharmaceutical risk management in 2000 as a new approach to drug safety. She has led the "Pharmaceutical Quality for the 21st Century Initiative" since 2002. This effort, to modernize pharmaceutical manufacturing and its regulation through the application of modern science and quality management techniques, has been highly successful in meeting its objectives. She has spearheaded an initiative on pharmacogenomics that has led to unprecedented agency-industry interactions on pharmacogenomics use in drug development. In 2004, she introduced FDA's "Critical Path" initiative, which is designed to improve the scientific basis for medical product development. Most recently, she launched the "Safety First" and "Safe Use" initiatives that are designed to improve drug safety management within and outside the FDA, respectively.

Dr. Woodcock was director of the Center for Drug Evaluation and Research (CDER) from 1994–2005. During this period, review processes for new and generic drugs were streamlined, while the standards for quality, safety and effectiveness were improved. Dr. Woodcock also oversaw initiatives to automate submission and review of applications and adverse event reports. Under Dr. Woodcock's leadership, CDER's regulatory decision-making was made more open and transparent to the public. Changes included publishing CDER's regulatory procedures and policies, developing over 100 technical "guidances" that describe regulatory standards, providing an unprecedented degree of participation of consumer and patient representatives in FDA processes, and creating an extensive Center web site which includes drug reviews and consumer information.

Prior to joining CDER, Dr. Woodcock was director of the Office of Therapeutics Research and Review, Center for Biologics Evaluation and Research (CBER). There she oversaw approval of the first biotechnology-based treatments for multiple sclerosis and cystic fibrosis. She also served as Acting Deputy Director of CBER for several years.

Plenary Session — Monday, October 24

SUPPORTED BY A GRANT FROM



John Lechleiter, Ph.D., Francis S. Collins, M.D., Ph.D., Sir Michael Rawlins, M.D.

On Monday October 24 at the Plenary Session, John Lechleiter, Ph.D., will speak to the future shape of the global pharmaceutical industry; Francis S. Collins, M.D., Ph.D., will speak on current research that may lead to new therapies in the future; and, Professor Sir Michael Rawlins will speak on the cost benefits of therapies and the societal ability to pay for the therapies.



John C. Lechleiter, Ph.D., has served as president and chief executive officer of Eli Lilly and Company since April 2008. He was named chairman of the board of directors in December 2008. In 2001, Lechleiter was appointed executive vice president for pharmaceutical products and corporate development.

In 2004, he became Lilly's executive vice president for pharmaceutical operations. And, in 2005, he was named president and chief operating officer and joined the board of directors.

Dr. Lechleiter received a bachelor of science degree in chemistry from Xavier University in 1975. He subsequently studied organic chemistry as a National Science Foundation Fellow at Harvard University, where he received his master's and doctorate degrees. In 2006, Dr. Lechleiter received an honorary doctorate of business administration from Marian University.



Francis S. Collins, M.D., Ph.D. is the Director of the National Institutes of Health (NIH). In that role he oversees the work of the largest supporter of biomedical research in the world, spanning the spectrum from basic to clinical research. Dr. Collins, a physician-geneticist noted for his landmark discoveries of disease genes and his leadership of the international Human

Genome Project, served as director of the National Human Genome Research Institute (NHGRI) at the NIH from 1993-2008. The Human Genome Project culminated in April 2003 with the completion of a finished sequence of the human DNA instruction book.

Dr. Collins received a B.S. in chemistry from the University of Virginia, a Ph.D. in physical chemistry from Yale University, and an M.D. with honors from the University of North Carolina at Chapel Hill. Prior to coming to the NIH in 1993, he spent nine years on the faculty of the University of Michigan, where he was a Howard Hughes Medical Institute investigator. He is an elected member of the Institute of Medicine and the National Academy of Sciences. Dr. Collins was awarded the Presidential Medal of Freedom in November 2007 and the National Medal of Science in 2009.



Sir Michael Rawlins, M.D. has been chairman of the National Institute of Health & Clinical Excellence (NICE) since its formation in 1999. He is also an Honorary Professor at the London School of Hygiene and Tropical Medicine, University of London, and Emeritus Professor at the University of Newcastle upon Tyne.

Sir Michael Rawlins was the Ruth and Lionel Jacobson Professor of Clinical Pharmacology at the University of Newcastle upon Tyne from 1973 to 2006. At the same time he held the position of consultant physician and consultant clinical pharmacologist to the Newcastle Hospitals NHS Trust. He

TABLE OF CONTENTS

REGISTRATION INFORMATION.....	6	WORKSHOPS (PRE-CONFERENCE EVENTS)	
2011 AAPS ANNUAL MEETING AND EXPOSITION SPONSORS	7	AAPS Workshop on Facilitating Oral Product Development and Reducing Regulatory Burden through Novel Approaches to Assess Bioavailability/Bioequivalence	102
ABOUT WASHINGTON, DC	9	AAPS Workshop on the Role of Pharmacogenetics (PGx) in Reducing Adverse Drug Reactions (ADRs)	103
AAPS EXPOSITION.....	10	AAPS Workshop on Pharmaceutical Stability: Scientific and Regulatory Considerations for Global Drug Development and Commercialization	103
DESCRIPTION OF AAPS SECTIONS	11	ASMS Workshop on High Resolution Mass Spectrometry in Drug Discovery and Drug Development: Current Applications and Future Perspectives	103
PROGRAM		CRS Workshop on Developing Pharmaceutical Products for Controlled Pulmonary Delivery	104
Meeting-at-a-Glance	13	NIAAA Symposium on Development and Applications of Biomarkers of Alcohol Abuse and Tissue Damage, Cancer and Neurodegeneration.....	104
SECTION PROGRAMMING TRACKS		SHORT COURSES (PRE-CONFERENCE EVENTS)	
General Programming.....	18	Short Course #1: Learning the Drug Discovery and Delivery Interface Process	51
Professional Development	22	Short Course #2: Understanding the Role of Mathematical Models in the Drug Development Paradigm	94
Analysis & Pharmaceutical Quality (APQ)	24	Short Course #3: Establishing Efficient Regulatory and Science-based Strategies for Seamless Technology Transfer from Development to Commercial Manufacturing: Roles of ICH Q8, Q9 and Q10.....	94
Biotechnology (BIOTEC).....	31	Short Course #4: PK/PD Systems Analysis: Hands-on Modeling with Adapt 5	41
Clinical Pharmacology & Translational Research (CPTR)	40	Short Course #5: Recent Advances in Non-invasive Drug Delivery of Biopharmaceuticals	57
Drug Design & Discovery (DDD).....	50	Short Course #6: PK and PK/PD Modeling of Biologics: Theory and Applications in Drug Discovery and Development.....	41
Formulation Design & Development (FDD).....	56		
Manufacturing Science & Engineering (MSE)	65		
Physical Pharmacy & Biopharmaceutics (PPB)	73		
Pharmacokinetics, Pharmacodynamics & Drug Metabolism (PPDM)	80		
Regulatory Sciences (RS)	93		
Pre-conference Workshops.....	102		

2011 AAPS Annual Meeting and Exposition

- Online Registration
- Registration Form

AAPS OPEN FORUMS (POST-CONFERENCE EVENTS)

Biomarker-companion Diagnostic Challenges in the Development of Personalized Medicines (CPTR)	45
Biosimilars: Regulatory Update and Practical Considerations for Successful Development and Approval (RS)	96
Drug Product Development Considerations and Challenges In Emerging Markets (MSE)	71
Successful Clinical Case Studies (DDD)	53
Novel Approaches to Address Challenges in Oral Dosage Form Development (FDD)	64
PPDM Lost in Translation: Utility of Preclinical Models of Human ADMET (PPDM)	92
Successful Interactions and Approvals with the FDA and Regulatory Agencies (PPB)	79
Therapeutic Equivalence of Complex Dosage Forms and Drug Products: Emerging Issues and Evolving Regulatory Standards (RS)	101
DBS and Microsampling: Moving Past the Hype to Knowledge and Implementation	30
Antibody Drug Conjugates: Bioanalytical Strategies and Validation to Fulfill both Good Scientific and Regulatory Requirements (BT)	39

REGISTRATION INFORMATION

3 Easy Ways to Register	105
Special Discounts	106
Spouse/Guest	106
Continuing Education (CE) Credits	107
International Registrants	107
Lost Badges and Expocards	107
Exposition Only	107
Cancellations/Refunds/Substitutions	107

SITE/HOTEL INFORMATION

What's Held Where?	108
Hotel Accommodations	112
Hotel Map	112

TRAVEL & TRANSPORTATION

Air Travel	113
Airport Transportation	113
Ground Transportation	113
Public Transportation	113
Parking	114
Driving Directions	114
Convention Center Shuttle	114

GENERAL INFORMATION

Contributed Papers	115
Professional Development	115
Graduate Students	115
About Children	115
Childcare Service	115
Family Friendly Activities	115
Speaker Information	116
Expocard	116
Photography	116
Electronic Devices	116
Recycling	116
Message Center/Internet Cafe	116
Business Center	116
Smoking Policy	116
What to Wear	116
AAPS Central	117
Get ROCK'd!	117
Wi-Fi Lounge	117
Student Lounge	117
Press Room	117
AAPS Fun Booth	117
AAPS on Social Media	117

MEMBERSHIP INFORMATION 118

UPCOMING AAPS ANNUAL EVENTS 118

TOURS	119
Tour Registration Form	120

STUDENT SHORT COURSE APPLICATION FORM 121

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.